INNOVACAP1,165.00

Innova Captab Limited

· Pharma & Health
₹ CrorePeersMOREPENLABIOLCPFDCSENORESSANOFIORCHPHARMAGUJTHEMRPGLIFEMcap ₹6,667 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation16.024.845.2
+ Impairment Loss / (Reversal)1.40.0-0.4
+ Finance Costs21.50.016.9
+ Interest Income-3.5-3.00.0
+ Fair Value (Gains) / Losses1.90.00.0
+ Unrealised FX (Gain) / Loss-0.70.5-1.7
+ Other Non-cash Items0.56.51.9
+ Other — Cash Effects are Investing / Financing0.00.20.0
+ Other Reconciling Items0.00.10.0
Changes in Working Capital
+ Inventories1.5-64.0-77.3
+ Trade Receivables — Current4.5-47.7-104.3
+ Other Financial Assets — Current0.0-29.4-26.8
+ Other Financial Assets — Non-current1.60.00.0
+ Other Current Assets3.2-3.2-14.8
+ Other Non-current Assets0.60.3-1.4
+ Trade Payables — Current6.323.7118.3
+ Other Financial Liabilities — Current-14.03.06.1
+ Other Current Liabilities2.70.3-5.3
+ Provisions — Current1.02.32.3
Cash from Operating Activities
Profit Before Tax (per I/S)129.5171.0188.3204.6
+ Total Adjustments (incl. Working Capital)44.5-85.9-41.2
Cash from Operations (pre-tax)174.085.2147.1
+ Interest Received — Operating0.00.0-4.3
+ Interest Paid — Operating0.0-2.40.0
+ Income Taxes Paid27.723.726.3
Cash from Operating Activities146.363.8116.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)287.4172.568.4
+ Disp of Fixed Assets0.00.37.0
+ Acq of Investment Property0.00.041.3
+ Disp of Investment Property0.10.00.0
+ Acq of Subsidiaries / Businesses (net)164.80.00.0
+ Interest Received — Investing2.53.92.8
+ Other Inflows / (Outflows) — Investing-49.416.7-7.3
Cash from Investing Activities-499.0-151.6-107.1
Cash from Financing Activities
+ Proceeds from Issue of Shares323.10.00.0
+ Proceeds from Borrowings168.8105.533.6
+ Repayment of Borrowings115.211.427.2
+ Payment of Lease Liabilities0.90.80.0
+ Interest Paid14.91.816.6
+ Dividends Paid0.00.011.4
+ Other Inflows / (Outflows) — Financing0.00.0-0.1
Cash from Financing Activities360.891.5-21.7
Net Changes in Cash (pre-FX)8.23.8-12.3
Net Changes in Cash8.23.8-12.3
Closing Cash11.7
Reference Items
EBITDA154.5186.2242.9259.5
EBITDA Margin %14.2814.9714.9014.83
Free Cash Flow (CFO − Capex)-141.0-108.748.248.2
Free Cash Flow to Equity-17.437.2
Free Cash Flow per Basic Share-24.64-18.998.428.42
Price to Free Cash Flow138.42
Cash Flow to Net Income1.550.500.83
Cash Paid for Taxes27.723.726.3
Cash Paid for Interest14.91.816.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.